All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Now you can personalise
your PsO and PsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Laura Coates, University of Oxford, Oxford, UK. We asked, What’s new in psoriatic arthritis (PsA) at EULAR 2022?
What’s new in PsA at EULAR 2022?
Coates summarized safety and outcome data from several studies that were presented at EULAR, including the COMPLETE-PsA study, as well as two studies that investigated bimekizumab. In addition, Coates discusses potential considerations when deciding which patients are suitable for treatment with a JAK inhibitor.
Laura Coates discusses the complications of selecting the correct treatment when there are multiple options available.
Bimekizumab is a humanized monoclonal IgG1 antibody that inhibits IL‑17A and IL‑17F and has demonstrated positive results in multiple phase III trials. In this article, we summarize the recent approvals...
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox